Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2007

Bradley to Make a $7M Milestone Payment to BioSante and Antares

  • The approval of a treatment for hot flashes in menopausal women triggered a $7-million milestone payment from Bradley Pharmaceuticals to two companies.

    In November 2006, Bradley Pharmaceuticals signed a marketing agreement with BioSante and its licensor, Antares Pharma, related to Elestrin in the U.S., through Bradley's Kenwood Therapeutics division.

    Under the terms of this agreement, BioSante will receive $5.25 million and Antares will get $1.75 million. Additionaly payments will be made to both companies in December 2007.

    BioSante reports that it retains the right to receive up to an additional $30 million upon the achievement of certain sales-based milestones. Antares says that regulatory- and sales-based payments could bring its total up to more than $13 million. The company will also receive a percentage of the royalties on third-party sales of Elestrin.

    Bradley expects to launch Elestrin in mid-2007 into the $1.3 billion estrogen market. It is a low-dose transdermal estradiol therapy delivered in Antares’ Advanced Transdermal Delivery gel system.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »